Hemogenic Endothelium Differentiation from Human Pluripotent Stem Cells in A Feeder- and Xeno-free Defined Condition
June 16th, 2019
10.3K views
Here, we present a protocol to precisely form hemogenic endothelium from human pluripotent stem cells in a feeder- and xeno-free condition. This method will have broad applications in disease modeling and screening for therapeutic compounds.
Overview
This article presents a protocol for generating hemogenic endothelium from human pluripotent stem cells in a feeder- and xeno-free environment. The method is designed to provide consistent yields and has potential applications in disease modeling and therapeutic screening.
Key Study Components
Area of Science
- Stem Cell Biology
- Hematology
- Immunology
Background
- Human pluripotent stem cells (hPSCs) can differentiate into various cell types.
- Hemogenic endothelium is crucial for blood cell development.
- Current methods may lack consistency in yield and efficiency.
- This study aims to improve the generation of hemogenic endothelial cells.
Purpose of Study
- To develop a reliable protocol for producing hemogenic endothelium from hPSCs.
- To facilitate applications in disease monitoring.
- To enable screening for therapeutic compounds.
Methods Used
- Coating plates with LM511-E8 for optimal cell growth.
- Inducing hemogenic differentiation under controlled conditions.
- Using flow cytometry to analyze cell surface markers.
- Employing a colony-forming unit assay to assess hematopoietic potential.
Main Results
- Successful generation of CD34-positive and CD45-positive hematopoietic progenitor cells.
- Demonstrated morphological changes from endothelial to hematopoietic cells.
- Confirmed the presence of hematopoietic colonies through flow cytometry.
- Established a reliable method for producing consistent yields of hemogenic endothelial cells.
Conclusions
- The protocol provides a robust approach for generating hemogenic endothelium.
- It has significant implications for research in hematology and immunology.
- This method can enhance the study of blood cell development and disease modeling.
Frequently Asked Questions
What is hemogenic endothelium?
Hemogenic endothelium is a specialized form of endothelial cells that can give rise to blood cells.
Why is LM511-E8 coating important?
LM511-E8 coating is crucial for the optimal growth and differentiation of human pluripotent stem cells.
How does this method benefit disease modeling?
This method allows for the generation of specific blood cell types that can be used to model various diseases.
What role do CD34 and CD45 play in this study?
CD34 and CD45 are markers used to identify hematopoietic progenitor cells during flow cytometry analysis.
Can this technique be used for gene editing?
Yes, the method can be applied for genetic interventions or gene editing of human blood cells.
Executive Industry Relevance
Deriving functional hematopoietic stem and progenitor cells from human pluripotent stem cells remains a critical challenge for autologous cell therapies targeting hematological disorders. This protocol delivers a cost-effective, feeder- and xeno-free method to generate hemogenic endothelium with consistent yields within four days, enabling reliable production of CD34+CD45+ clonogenic progenitors. The approach supports disease modeling and therapeutic compound screening by providing a scalable, defined system for hematopoietic development studies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of hematopoietic differentiation pathways through inducible hemogenic endothelium formation.
- Operational Value: Provides a defined, reproducible system for validating genetic targets in blood cell development.
Screening & Assay Development
- Scientific Value: Produces hematopoietic progenitor cells suitable for compound screening in methylcellulose-based colony-forming assays.
- Operational Value: Delivers quantifiable colony-forming unit outputs (38 CFU per 10,000 cells) for dose-response and toxicity profiling.
Translational & Preclinical Research
- Scientific Value: Supports generation of granulocyte and macrophage colonies from differentiated progenitors, enabling immune cell modeling.
- Operational Value: Facilitates off-the-shelf production of functional blood cells for preclinical efficacy and safety testing.
Pipeline & Workflow Integration
The method integrates into the discovery continuum by enabling hemogenic endothelium generation as an upstream step to hematopoietic progenitor production and functional validation.
- Discovery Biology: Supports hypothesis testing of transcription factors and signaling cues in endothelial-to-hematopoietic transition.
- Screening: Delivers standardized hematopoietic progenitors for compound library screening in clonogenic assays.
- Analytics: Employs flow cytometry for CD34/CD45 co-expression quantification and colony-forming unit assays for functional output.
- Translational Research: Enables modeling of human hematopoietic development and immune cell production for preclinical studies.
- Enterprise Reuse: Defined, xeno-free conditions allow platform adaptation across multiple cell lines and genetic backgrounds.
Operational & Enterprise Impact
- Scientific Value: Reduces variability in hematopoietic differentiation, increasing predictive confidence in target validation.
- Operational Value: Eliminates feeder and xenogeneic components, enhancing reproducibility and scalability for GMP-adjacent workflows.
- Strategic Value: Enables risk-adjusted go/no-go decisions in hematopoietic therapy development through reliable progenitor yields.
- Portfolio Impact: Supports prioritization of hematopoietic targets by providing a consistent source for preclinical profiling.
Implementation Considerations
- Requires expertise in stem cell culture, spheroid formation, and hypoxic differentiation techniques.
- Dependent on LM511-E8 matrix coating for optimal pluripotent stem cell adhesion and spheroid precision.
- Necessitates flow cytometry and colony-forming unit assay infrastructure for hematopoietic progenitor validation.
- Involves timed medium changes and hypoxia exposure, demanding precise process control.
- Limited by the requirement for manual spheroid tallying as a key deterministic factor in efficiency.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in hemogenic endothelium differentiation?
Null hypothesis testing ensures observed hematopoietic progenitor generation exceeds random variation, confirming that differentiation protocols like LM511-E8 coating and hypoxic induction drive statistically significant endothelial-to-hematopoietic transition.
How does independent variable isolation fit the discovery pipeline for hematopoietic progenitor production?
Isolating variables such as matrix coating, spheroid density, and medium composition enables attribution of hematopoietic output to specific protocol steps, supporting target de-risking in early discovery.
What quantitative dependent variable measurements enable assessment of hematopoietic potential in this protocol?
Flow cytometry quantification of CD34+CD45+ cells and colony-forming unit assays measuring granulocyte/macrophage colonies provide quantitative endpoints for evaluating differentiation efficiency and functional progenitor yield.
Why do replication requirements matter for cross-functional collaboration in hematopoietic differentiation workflows?
Reproducible hemogenic endothelium generation across experiments ensures consistent progenitor production, enabling reliable data sharing between discovery, screening, and preclinical teams for aligned decision-making.
What statistical analysis capabilities are required before implementing this hematopoietic differentiation protocol?
Implementation requires capability to perform colony-forming unit counting, flow cytometry percentage analysis, and statistical comparison of CD34/CD45 co-expression and CFU yields across experimental conditions.
Chapters in this video
0:04
Title
1:11
Pluripotent Stem Cell Colony Formation
2:45
Hemogenic Induction and Isolation of Hemogenic Endothelium
4:08
Induction of Endothelial-to-hematopoietic Transition (EHT)
5:00
Flow Cytometry Analysis of Hematopoietic Cells
6:27
Colony Forming Unit Assay of Hematopoietic Cells
7:30
Results: Hemogenic Induction
8:19
Conclusion
